Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines

Investigational New Drugs

Volumn 29, Issue 2, 2011, Pages 392-395

  Celeghini, Claudio ^a   Voltan, Rebecca ^a   Rimondi, Erika ^a   Gattei, Valter ^c   Zauli, Giorgio ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cell cycle; P53 status; Perifosine; Retinoblastoma

Indexed keywords

PERIFOSINE; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; DRUG DERIVATIVE; E2F1 PROTEIN, HUMAN; PHOSPHORYLCHOLINE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; CELL CYCLE; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; GENETICS; LEUKEMIA; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; E2F1 TRANSCRIPTION FACTOR; HUMANS; LEUKEMIA; MUTATION; PHOSPHORYLCHOLINE; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957485214     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-009-9370-1     Document Type: Article

References (9)

1. van Blitterswijk WJ, Verheij M (2008) Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 14:2061-2074
2. Nyakern M, Cappellini A, Mantovani I, Martelli AM (2006) Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 5:1559-1570 (Pubitemid 44070493)
3. Tazzari PL, Tabellini G, Ricci F et al (2008) Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Res 68:9394-9403
4. Mitani N, Niwa Y, Okamoto Y (2007) Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem 44:557-559 (Pubitemid 351724640)
5. Secchiero P, Zerbinati C et al (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395-403 (Pubitemid 46780067)
6. Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126-135 (Pubitemid 36753853)
7. Secchiero P, Zerbinati C, Rimondi E et al (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965-1974 (Pubitemid 39094803)
8. Zauli G, Visani G, Bassini A et al (1996) Nuclear translocation of protein kinase C-α and -ζ isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid (ATRA). Br J Haematol 93:542-550
9. Chen HZ, Tsai SY, Leone G (2009) Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 9:785-797